MedX Health Corp Acquires RJ-Laser Canadian Operations

    
       MedX Acquires Approved Products for Veterinary and Dermatology

                 MedX Strengthens Product Mix Within Existing
             Rehab/Chiropractic, Dental and Acupuncture Markets
    

MISSISSAUGA, ON, March 23 /CNW/ - MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, today announced it has acquired the Canadian operations of 27 year old laser pioneer, Reimers & Janssen GmbH (herein after "RJ-Laser"), providing an expanded line of products, with improved product features, within MedX's existing rehab/chiropractic, dental, and acupuncture laser and light markets, as well as approved products ready for launch to Veterinarians and Dermatologists.

"Louie Canitano, the President of RJ-LASER Canada, will be joining the MedX management team as the Executive Vice President of Operations. Louie has a broad range of skills and expertise within the laser field, acquired over the past 11 years, including design, development, manufacturing, regulatory affairs, and sales and marketing, and his leadership will help accelerate rapid growth of laser and related products and devices within all markets," says Steve Guillen, President and CEO of MedX Health.

RJ-LASER and MedX plan to expand their business partnership throughout 2010. RJ-LASER is currently approved by CE, Health Canada, and recently received FDA approval for many of their laser products.

"I am very excited about joining forces with the MedX team. Together I am confident that we can continue to build upon our existing chiropractic, physiotherapy, dental, and acupuncture markets, and rapidly expand our products into high growth veterinary and dermatology sectors in offering the clinician the widest selection of laser devices and related products creating a one stop laser shop," said Mr. Canitano.

About RJ-LASER

RJ-LASER, (http://www.rj-laser.com/) is a worldwide market leader in non-invasive laser therapy. The RJ-LASER systems are based on their 27 years of experience within the development and production of medical laser devices (LLLT). RJ-LASER is dedicated to offering both conventional and complementary/holistic treatment possibilities. RJ-LASER offers the widest range of medical lasers for the diagnostic as well as for biostimulation and biomodulation. RJ-Laser device configurations consist of single probes, multi cluster probes and scanners in addition to the new patent pending LightNeedle.

RJ-LASER devices use a proprietary and ultra sophisticated software operating system for the ultimate in advanced clinical information and treatment settings. The RJ-Laser software operating system provides today's demanding clinicians with the widest selection of specialized treatment modalities backed up with the latest clinical research according to WALT.

RJ-Laser manufactures and sells worldwide including Canada and the US with the recent approval of FDA (510K) for Handylaser Trion, Handylaser Sprint, LaserPen, Physiolaser Olympic, and PolyLaser Trion.

About MedX Health Corp.

MedX is a leading North American developer and manufacturer of low level laser and light medical devices for the drug free and non-invasive treatment of tissue damage and pain in numerous medical settings including dental, rehabilitation and wound care. MedX is the world's only company focusing on developing and delivering a broad cross-section of technologies and products involved in healing using light therapy. MedX is committed to advocating for, the bringing of non-invasive, drug-free healing nature of light to people seeking relief from pain and other physical ailments.

MedX's strategy is to build upon its success in bringing relief of conditions in a non-pharmacologic manner in the rehabilitation market through key partnerships, acquisitions, strong patent protection as well as developing and commercializing advanced products in the dental and wound-care markets that will position the company to increase revenue. In addition, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market: its "Photobandage(TM)", a bandage technology that allows a wound to be bathed in light, designed to enhance the healing process. The Company intends to license this new technology to one or more major wound care companies for further development of marketing and sales.

Brand products are US FDA approved, Health Canada cleared, and CE Marked and are produced in an ISO 9001 and 13485 certified manufacturing and testing facility. For a complete profile of MedX Health Corp. and its products visit www.medXhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

%SEDAR: 00017466E

For further information: Investors: Steve Guillen, President and Chief Executive Officer, MedX Health Corp., Phone: [phone], [email protected]; Media: Louie Canitano, Executive Vice President of Operations, MedX Health Corp., Phone: [phone] ext: 222, [email protected]